Program
finerenone
Also written as “BAY94-8862”, “Finerenone (BAY94-8862)” and “Finerenone (Kerendia, BAY94-8862)”.
Its studies are mostly in Renal Insufficiency, Chronic · Heart Failure · Diabetic Nephropathies · Ventricular Dysfunction, Left · Diabetes Mellitus, Type 2, led by Bayer.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 254 open or running | phase 4since Jan 20, 2023 | Apr 29, 2011 | Apr 10, 2027phase 3 · NCT05196035 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Apr 29, 2011.
- Sep 2, 20152 phase 3 studiesNCT02545049, NCT02540993
- Nov 3, 20162 phase 1 studies in PharmacokineticsNCT02956109, NCT02957396
- Jun 15, 2020Phase 3 study in Heart FailureNCT04435626 · 6,016 enrolled · United States, Argentina, Australia and more
- Feb 26, 2021No phase study in Diabetic RetinopathyNCT04795726 · 70 enrolled · Bulgaria, United Kingdom
- May 6, 20212 phase 1 studiesNCT04881994, NCT04908436
- Jul 20, 2021Phase 2 study in Renal Insufficiency, ChronicNCT05013008 · 951 enrolled · United States, Australia, Austria and more
- Sep 12, 2021Phase 3 study in Non-diabetic Chronic Kidney DiseaseNCT05047263 · 1,584 enrolled · United States, Argentina, Australia and more
- Jan 7, 2022Phase 3 study in Renal Insufficiency, ChronicNCT05196035 · 219 enrolled · United States, Argentina, Australia and more
- Feb 4, 2022Phase 2 study in Diabetes Mellitus, Type 2NCT05254002 · 1,664 enrolled · United States, Belgium, Canada and more
- Jul 11, 2022Phase 3 study in Renal Insufficiency, ChronicNCT05457283 · 100 planned · United States, Argentina, Australia and more
- Jan 20, 2023Phase 4 study in Renal Insufficiency, ChronicNCT05705271 · 200 enrolled · India
- Jun 5, 2023Phase 3 study in Renal Insufficiency, ChronicNCT05901831 · 242 enrolled · United States, Canada, China and more
- Aug 6, 2025Phase 1 study in Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per CentNCT07116512 · 60 enrolled · Germany
- Sep 8, 20252 phase 3 studies in Ventricular Dysfunction, LeftNCT07188805, NCT07192952
Ahead
- Apr 10, 2027Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT05196035
- Aug 7, 2028Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT05457283
- Nov 30, 2029Primary completion: phase 3 study in Ventricular Dysfunction, LeftNCT07188805
- Dec 30, 2030Primary completion: phase 3 study in Ventricular Dysfunction, LeftNCT07192952
TargetBeta
“Mineralocorticoid receptor antagonist”ChEMBL 37, by rule
Other programs on NR3C2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| drospirenonerule | estetra | phase 4 | 20 |
| vamorolonerule | reveragen-biopharma-inc | phase 4 | 11 |
| Spironolactonerule | cmp-development-llc | phase 4 | 8 |
| balcinrenonerule | AstraZeneca | phase 3 | 15 |
| HRS-1780 | Jiangsu HengRui Medicine | phase 3 | 7 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07192952Ventricular Dysfunction, Left · United States, Argentina, Austria and more | 3 | Recruiting | Dec 30, 2030 | 117 |
| NCT07188805Ventricular Dysfunction, Left · United States, Argentina, Austria and more | 3 | Recruiting | Nov 30, 2029 | 111 |
| NCT07116512Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent · Germany | 1 | Completed | Jul 28, 2023 | 60 |
| NCT05901831Renal Insufficiency, Chronic · United States, Canada, China and more | 3 | Completed | Aug 20, 2025 | 242 |
| NCT05705271Renal Insufficiency, Chronic · India | 4 | Completed | Jul 3, 2025 | 200 |
| NCT05457283Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Recruiting | Aug 7, 2028 | 100 |
| NCT05254002Diabetes Mellitus, Type 2 · United States, Belgium, Canada and more | 2 | Completed | Mar 14, 2025 | 1,664 |
| NCT05196035Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 10, 2027 | 219 |
| NCT05047263Non-diabetic Chronic Kidney Disease · United States, Argentina, Australia and more | 3 | Completed | Dec 31, 2025 | 1,584 |
| NCT05013008Renal Insufficiency, Chronic · United States, Australia, Austria and more | 2 | Completed | Dec 31, 2021 | 951 |
| NCT04908436Renal Insufficiency, Chronic · Germany | 1 | Completed | May 5, 2011 | 33 |
| NCT04881994Diabetic Nephropathies · Germany | 1 | Completed | Sep 16, 2014 | 27 |
| NCT04795726Diabetic Retinopathy · Bulgaria, United Kingdom | – | Completed | Jun 30, 2021 | 70 |
| NCT04435626Heart Failure · United States, Argentina, Australia and more | 3 | Completed | May 15, 2024 | 6,016 |
| NCT02957396Pharmacokinetics · Germany | 1 | Completed | Jan 13, 2017 | 16 |
| NCT02956109Pharmacokinetics · Germany | 1 | Completed | Dec 22, 2016 | 16 |
| NCT02545049Diabetic Nephropathies · United States, Argentina, Australia and more | 3 | Completed | Feb 2, 2021 | 7,352 |
| NCT02540993Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Completed | Apr 14, 2020 | 5,734 |
| NCT01968668Diabetic Nephropathies · Japan | 2 | Completed | Oct 9, 2014 | 96 |
| NCT01955694Heart Failure · Japan | 2 | Completed | Jan 23, 2015 | 72 |
| NCT01874431Diabetic Nephropathies · United States, Australia, Austria and more | 2 | Completed | Jul 9, 2014 | 823 |
| NCT01807221Heart Failure · United States, Australia, Austria and more | 2 | Completed | Nov 11, 2014 | 1,066 |
| NCT01687920Heart Failure · Germany | 1 | Completed | Nov 28, 2012 | 25 |
| NCT01473108Clinical Pharmacology · Germany | 1 | Completed | Nov 30, 2010 | 67 |
| NCT01345656Heart Failure · Austria, Belgium, Czechia and more | 2 | Completed | May 30, 2012 | 457 |
How it is read
Names in the registry
- “BAY94-8862”, 10 entries
- “Finerenone (BAY94-8862)”, 9 entries
- “Finerenone (Kerendia, BAY94-8862)”, 6 entries
- “BAY 94-8862”, 2 entries
- “Finerenone”, 1 entry
Conditions, from the studies’ own filings
- Renal Insufficiency, Chronic, 7 studies
- Heart Failure, 6 studies
- Diabetic Nephropathies, 4 studies
- Ventricular Dysfunction, Left, 2 studies
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.